Literature DB >> 33280407

Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion.

Mohammed Siddiqui1, Eric K Judd2, Bin Zhang3,4, Tanja Dudenbostel1, Robert M Carey5, Suzanne Oparil1, David A Calhoun1.   

Abstract

Masked uncontrolled hypertension (MUCH) in treated patients is defined as controlled office blood pressure (BP) but uncontrolled out-of-clinic ambulatory BP. Previously, we have shown that patients with MUCH have evidence of heightened out-of-clinic sympathetic nervous system activity. The aim is to test the hypothesis that MUCH patients have higher aldosterone secretion compared with patients with true controlled hypertension. Two hundred twenty-two patients were recruited after having controlled office BP readings at ≥3 clinic visits. Patients taking MR (mineralocorticoid receptor) antagonists and epithelial sodium channel blockers were excluded. All patients were evaluated by clinic automated office BP and morning serum aldosterone and plasma renin activity. Out-of-clinic ambulatory BP monitoring and 24-hour urinary aldosterone, catecholamines, and metanephrines were also measured. Sixty-four patients had MUCH, and the remaining 48 patients had true controlled hypertension. MUCH patients had significantly higher out-of-clinic levels of 24-hour urinary aldosterone, catecholamines, and metanephrines compared with true controlled hypertension. The 2 groups did not differ in serum aldosterone, plasma renin activity, or aldosterone-renin ratio collected in clinic. In addition, 32.8% of MUCH patients had high out-of-clinic 24-hour urinary aldosterone (≥12 µg) but normal clinic serum aldosterone (<15 ng/dL) and aldosterone-renin ratio (<20). Further, in correlation matrix analysis, higher 24-hour urinary catecholamines and metanephrines were associated with higher 24-hour urinary aldosterone and plasma renin activity levels in MUCH patients. Patients with MUCH have higher out-of-clinic urinary aldosterone levels compared with patients with true controlled hypertension. This study suggests that patients with MUCH likely have higher out-of-clinic sympathetic nervous system tone increases aldosterone secretion mediated by increased renin release that may contribute to their higher out-of-clinic BP.

Entities:  

Keywords:  aldosterone; ambulatory care; ambulatory care facilities; humans; renin

Mesh:

Substances:

Year:  2020        PMID: 33280407      PMCID: PMC7855795          DOI: 10.1161/HYPERTENSIONAHA.120.15950

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  41 in total

1.  A reference method for the analysis of aldosterone in blood by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.

Authors:  V F Fredline; P J Taylor; H M Dodds; A G Johnson
Journal:  Anal Biochem       Date:  1997-10-15       Impact factor: 3.365

2.  Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study.

Authors:  Daichi Shimbo; Jonathan D Newman; Joseph E Schwartz
Journal:  Am J Hypertens       Date:  2012-03-01       Impact factor: 2.689

3.  Changes of blood pressure patterns and target organ damage in patients with chronic kidney disease: results of the APrODiTe-2 study.

Authors:  Ran-Hui Cha; Hajeong Lee; Jung Pyo Lee; Eunjeong Kang; Young Rim Song; Yon Su Kim; Sung Gyun Kim
Journal:  J Hypertens       Date:  2017-03       Impact factor: 4.844

4.  Prevalence of Masked Hypertension in Untreated and Treated Patients With Office Blood Pressure Below 130/80 mm Hg.

Authors:  Alejandro de la Sierra; José R Banegas; Ernest Vinyoles; Julián Segura; Manuel Gorostidi; Juan J de la Cruz; Luis M Ruilope
Journal:  Circulation       Date:  2018-04-30       Impact factor: 29.690

5.  Quantification of unconjugated metanephrines in human plasma without interference by acetaminophen.

Authors:  M Roden; W Raffesberg; W Raber; E Bernroider; B Niederle; W Waldhäusl; S Gasic
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

6.  Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence.

Authors:  Mohammed Siddiqui; Eric K Judd; Tanja Dudenbostel; Bin Zhang; Pankaj Gupta; Maciej Tomaszewski; Prashanth Patel; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2019-07-22       Impact factor: 10.190

Review 7.  Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association.

Authors:  Paul Muntner; Daichi Shimbo; Robert M Carey; Jeanne B Charleston; Trudy Gaillard; Sanjay Misra; Martin G Myers; Gbenga Ogedegbe; Joseph E Schwartz; Raymond R Townsend; Elaine M Urbina; Anthony J Viera; William B White; Jackson T Wright
Journal:  Hypertension       Date:  2019-05       Impact factor: 10.190

8.  Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease.

Authors:  Velvie Pogue; Mahboob Rahman; Michael Lipkowitz; Robert Toto; Edgar Miller; Marquetta Faulkner; Stephen Rostand; Leena Hiremath; Mohammed Sika; Cynthia Kendrick; Bo Hu; Tom Greene; Lawrence Appel; Robert A Phillips
Journal:  Hypertension       Date:  2008-12-01       Impact factor: 10.190

Review 9.  Masked hypertension: a systematic review.

Authors:  Guillaume Bobrie; Pierre Clerson; Joël Ménard; Nicolas Postel-Vinay; Gilles Chatellier; Pierre-François Plouin
Journal:  J Hypertens       Date:  2008-09       Impact factor: 4.844

10.  Sexual dimorphism in the transition from masked to sustained hypertension in healthy youths.

Authors:  Empar Lurbe; Lutgarde Thijs; Maria Isabel Torro; Julio Alvarez; Jan A Staessen; Josep Redon
Journal:  Hypertension       Date:  2013-06-03       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.